Results 231 to 240 of about 2,700,197 (262)

Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS. [PDF]

Biomedicines
Goyal NA, Andrews JA, Oskarsson BE, Wiedau MH, Kasarskis EJ, Forrest BD, Zhang R, Bracci PM, Davis MW, Azhir A, McGrath MS.   +10 more
europepmc   +1 more source

Planning a Clinical Practice Guideline Revision for a Core Set of Outcome Measures in Adults Undergoing Neurologic Physical Therapy, Part 1: Assessing Dissemination and Scholarly Uptake

Clinical and Public Health Guidelines, Volume 3, Issue 4, October 2026.
ABSTRACT Introduction Clinical Practice Guidelines (CPGs) facilitate evidence‐based decision‐making and standardising care, yet their dissemination and scholarly uptake vary widely. The Core Set of Outcome Measures for Adults With Neurologic Conditions Undergoing Rehabilitation CPG (Core Set) has been broadly referenced within neurologic physical ...
Jennifer L. Moore, Jane E. Sullivan, Marghuretta Bland, Wendy Romney, Elizabeth Anderl, Zeynep Gulen Erkoc, Kirsten Potter   +6 more
wiley   +1 more source

Optimizing deep learning models to combat amyotrophic lateral sclerosis (ALS) disease progression. [PDF]

Digit Health
Qin H, Hussain L, Liu Z, Yan X, Awwad FA, Butt FM, Salaria UA, Ismail EAA.   +7 more
europepmc   +1 more source

Advancements in genetic research and RNA therapy strategies for amyotrophic lateral sclerosis (ALS): current progress and future prospects. [PDF]

J Neurol
Ruffo P, Traynor BJ, Conforti FL.
europepmc   +1 more source

Vitamin D and Neurodegenerative Diseases Such as Multiple Sclerosis (MS), Parkinson's Disease (PD), Alzheimer's Disease (AD), and Amyotrophic Lateral Sclerosis (ALS): A Review of Current Literature. [PDF]

Curr Nutr Rep
Savran Z, Baltaci SB, Aladag T, Mogulkoc R, Baltaci AK.   +4 more
europepmc   +1 more source

Respiratory Function Improvement and Lifespan Extension Following Immunotherapy with NP001 Support the Concept That Amyotrophic Lateral Sclerosis (ALS) Is an Immuno-Neurologic Disease. [PDF]

Int J Mol Sci
Zhang R, Azhir A, McGrath MS.
europepmc   +1 more source

Effect of Edaravone Therapy on Amyotrophic Lateral Sclerosis Functional Rating Score (ALS-FRS) in Patients of Amyotrophic Lateral Sclerosis (ALS) in Central India: A Retrospective Open Label Study. [PDF]

Ann Neurosci
Kashyap PV, Singh D, Nair A, Jaiswal A, Pandey V.   +4 more
europepmc   +1 more source

Resting-State EEG Oscillations in Amyotrophic Lateral Sclerosis (ALS): Toward Mechanistic Insights and Clinical Markers. [PDF]

J Clin Med
Chmiel J, Stępień-Słodkowska M.
europepmc   +1 more source

Efficacy of pain management strategies in adults with Amyotrophic Lateral Sclerosis (ALS): A Systematic Review. [PDF]

Neurol Sci
Rojas-López JC, Estrada-Gualdron PI, Ramírez-Guerrero S, Velásquez-Cárdenas MJ, Redondo-Escobar J, Vargas-Arenas S, Palacios-Sánchez L, Palacios-Espinosa X.   +7 more
europepmc   +1 more source

Comment on ‘The Values and Preferences of People Living With Motor Neurone Disease (MND): A Systematic Review and Meta‐Analysis’

Clinical and Public Health Guidelines, Volume 3, Issue 4, October 2026.
Rachna Rohtagi, Parag Jayant Ratnakar, Deepti M. Sati, Hariharan Srinivasan   +3 more
wiley   +1 more source